Meet the Team

Executives

Profile.Rapisarda.Antony.Transparent.png

Antony Rapisarda

Inventor of the SynvIchor™ technology based on the ELIJA clinical trial in Queensland, Australia. Previously successful commercialization of SeptiCyte™ technology, for Immunexpress, in Seattle USA. Medical doctor currently training in Orthopaedic Surgery in Australia and PhD candidate in Molecular Genomics at Queensland University of Technology. Over 15 years of tertiary academic research and education combined with unique business opportunities in the USA for equally novel technologies.

Chief Executive Officer

Profile.Holtom.Luke.Transparent.png

Luke Holtom

A Chartered Accountant and qualified specialist in commercial banking, tax and insolvency. Successful winner of the Ferrier Hodgson internship program. Following a successful career in Australia, Mr Holtom began an international career working with FTSE UK 100 Companies and now works for the largest UK Bank, Lloyds Banking Group (“LBG”). With his extensive experience in corporate restructuring, tax accounting, and internal audit Mr Holtom was brought into LBG and tasked with working in Tax, Accounting and Risk Management. 

Chief Financial Officer

Profile.Cardona.Dave.Transparent.png

David Cardona

Mr Cardona brings 22 years of IT experience and technical leadership to the team. With a proven track record of delivering solutions across software, hardware and platform architecture, software engineering, data management and development operations. With a keen focus in artificial intelligence and machine learning, David has seen the successful architecture, development and delivery of critical systems within laboratory information, robotics, manufacturing, finance and  ecommerce technologies.

Chief Technology Officer

Scientific Advisors

Matthew_Hartley_crop.png

Consultant Surgeon at The Pindara Private Hospital. Dr Hartley is the lead surgeon for robot assisted joint replacements in Australia. He specialises in hip and knee replacements, knee arthroscopies, ACL reconstructions and revision joint replacements. 

Hartley-Logo.png

Dr. Matthew Hartley

Consultant Orthopaedic Surgeon

5104.jpeg

Professor of Anaesthesia and Critical Care at The University of Queensland and is a key advisor for cohort development and grant applications.

blank-white.png

Prof. Jeffery Lipman

Professor of Anaesthesia and Critical Care Medicine

TETSWORTH_aa0cc1a7fe3a76c2f064bc5b0c8153d5_edited.png

Consultant Surgeon at The Royal Brisbane and Women's Hospital and is a key advisor for collaboration partners internationally.

blank-white.png

A/Prof. Kevin Tetsworth

Consultant Orthopaedic Surgeon

009_edited_edited_edited_edited.png

A/Professor of Orthopaedics at The University of Adelaide, the Lyell McEwin and Modbury public hospitals (SA Health). Visiting Orthopaedic Specialist at Calvary North Adelaide, Western and Ashford private hospitals. Key advisor on cohort validation and grant applications.

Kurmis Orthopaedics_final_Logo 3.jpg

A/Prof. Andrew Kurmis

Consultant Orthopaedic Surgeon

Corporate Governance Board

Michael_Ribot_edited.png

CEO of Global Orthopaedics, Mr Ribot presided over the commercialisation and expansion of Global Orthopaedics for 20 years prior to acquisition in 2018. Since the successful exit, Mr Ribot has been on boards and works to offer his wide knowledge and experience as a CEO coach. Mr Ribot will bring a wealth of experience in commercialising Orthopaedic technology to the board at OrthoDx.

Michael Ribot

Chairman

Profile.Rapisarda.Antony.Transparent.png

Inventor of the SynvIchor™ technology based on the ELIJA clinical trial in Queensland, Australia. Previously successful commercialization of SeptiCyte™ technology, for Immunexpress, in Seattle USA. Medical doctor currently training in Orthopaedic Surgery in Australia and PhD candidate in Molecular Genomics at Queensland University of Technology. Over 15 years of tertiary academic research and education combined with unique business opportunities in the USA for equally novel technologies.

Antony Rapisarda

Executive Director

Victor.Argaet_edited.png

Principal at Davies Collison Cave, Dr Victor Argaet specializes in patent applications in all areas of biotechnology, including immunology, molecular biology, bioinformatics and diagnostics. With a PhD in biochemistry and molecular biology from the University of Melbourne, post-doctoral experience at the Walter and Eliza Hall Institute of Medical Research and the Queensland Institute of Medical Research, as well as over 27 years in the patent attorney profession, including 20 years as a DCC partner or principal, Victor has been instrumental in the preparation and submission of OrthoDx's international patent application for Synovial Biomarkers.

Dr. Victor Argaet

Non-Executive Director

Profile.Holtom.Luke.Transparent.png

A Chartered Accountant and qualified specialist in commercial banking, tax and insolvency. Successful winner of the Ferrier Hodgson internship program. Following a successful career in Australia, Mr Holtom began an international career working with FTSE UK 100 Companies and now works for the largest UK Bank, Lloyds Banking Group (“LBG”). With his extensive experience in corporate restructuring, tax accounting, and internal audit Mr Holtom was brought into LBG and tasked with working in Tax, Accounting and Risk Management. 

Luke Holtom

Executive Director

6559646-1x1-340x340_edited_edited.png

I'm a paragraph. Click here to add your own text and edit me. It's easy.

Dr. Richard Hocking

Non-Executive Director